Efficacy News and Research

RSS

Cardiovascular considerations crucial for CML TKI patients

A review of BCR–ABL1 tyrosine kinase inhibitors highlights the need to consider cardiovascular adverse event risk profiles when prescribing for patients with chronic myeloid leukaemia.

22 Jan 2016

Adjuvant Chemotherapy Colon Cancer Trials Should ‘Stratify By MSI, KRAS, BRAF’

A post hoc analysis of the PETACC-8 trial has revealed an interaction between microsatellite instability and BRAF and KRAS mutation status when determining the prognosis of patients with resected stage III colon adenocarcinoma.

22 Jan 2016

UAB study shows IL-37 protein suppresses inflammatory response after spinal cord injury

Spinal cord injuries cause severe functional disabilities in those who sustain them, including paraplegia or tetraplegia, depending on the scale of the injury. This is due to the degeneration of the spinal pathways that carry nerve signals from the brain to the different parts of the body and vice versa, resulting in loss of mobility and sensitivity underneath the injured area.

22 Jan 2016

Researchers use ASC secreted factors to create therapeutic factor concentrate for critical limb ischemia

"Critical limb ischemia" (CLI) describes an advanced stage of peripheral artery disease characterized by obstruction of the arteries and a markedly reduced blood flow to the extremities. CLI identifies patients at high-risk for major amputation. The estimated annual incidence of CLI ranges between 500 and 1000 new cases out of one million people per year, with the highest rates among the elderly, smokers, and those with diabetes. CLI is considered to be a critical public health issue. Attempts at revascularization are often unsuccessful.

22 Jan 2016

Oral drug ivacaftor appears to be safe, beneficial to pre-school children with specific type of cystic fibrosis

The oral drug ivacaftor appears to be safe and could be beneficial to young children between the ages of 2 and 5 with a specific type of cystic fibrosis, according to new research published in The Lancet Respiratory Medicine journal.

22 Jan 2016

Lilly receives FDA approval for Humulin R U-500 KwikPen

The U.S. Food and Drug Administration has approved Eli Lilly and Company's Humulin R U-500 KwikPen(insulin human injection) 500 units/mL, a pre-filled device containing Humulin R U-500, a highly concentrated formulation of insulin.

21 Jan 2016

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan plc announced today the publication of the positive results of the Phase III trials of VIBERZITM C IV (eluxadoline) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in the January 21 issue of The New England Journal of Medicine.

21 Jan 2016

Immunotherapy could be the future of cancer treatments

For decades most cancers have been treated with the standard of care treatments which typically include surgery, radiation and/or chemotherapy. Now there is talk that immunotherapy represents "the future of cancer treatments."

21 Jan 2016

Gene therapy holds considerable potential for safe, effective treatment of people with factor VII deficiency

Hematology researchers have used a single injection of gene therapy to correct a rare bleeding disorder, factor VII deficiency, in dogs. This success in large animals holds considerable potential for a safe, effective and long-lasting new treatment in humans with the same bleeding disorder.

21 Jan 2016

Mood disorder experts question effectiveness of metyrapone drug

Pioneering research by mood disorder experts at Newcastle University has questioned the effectiveness of metyrapone, a drug suggested to treat depression.

21 Jan 2016

Novel gene therapy treatment proves safe, effective for factor VII deficiency

A single injection. That's all someone with a factor VII deficiency would need for a life-long cure, thanks to a new gene therapy treatment developed in a collaboration of researchers at the University of North Carolina and The Children's Hospital of Philadelphia.

20 Jan 2016

New Georgia Tech research center launched to manufacture living cells for cell-based therapies

A $15.7 million grant from the Atlanta-based Marcus Foundation has helped launch a new Georgia Institute of Technology research center that will develop processes and techniques for ensuring the consistent, low-cost, large-scale manufacture of high-quality living cells used in cell-based therapies.

20 Jan 2016

Physiotherapy and occupational therapy not effective in patients with Parkinson's disease

New research from the University of Birmingham has shown that physiotherapy and occupational therapy do not produce improvements in quality of life for patients with mild to moderate Parkinson's disease.

20 Jan 2016

$SIRIUS supports single-agent daratumumab in refractory multiple myeloma$

SIRIUS supports single-agent daratumumab in refractory multiple myeloma

Phase II trial results show that daratumumab monotherapy elicits responses and has a favourable adverse event profile in heavily-pretreated, refractory multiple myeloma patients.

19 Jan 2016

Stem cell transplantation of neurotrophic factors shows promise in ALS

Mesenchymal stem cells cultured to secrete neurotrophic factors can be administered to patients with amyotrophic lateral sclerosis without lasting unwanted effects and may have clinical benefits, indicates a phase I/II safety analysis study.

19 Jan 2016

Text message reminders may help reduce people’s blood pressure

The study, of over 1300 adults with high blood pressure in the Cape Town area, compared text message reminders and interactive text messaging to a control group receiving standard care. The results appear online in the American Heart Association journal Circulation.

19 Jan 2016

First patients treated in Phase 1b trial of pembrolizumab with REOLYSIN in advanced pancreatic adenocarcinoma

Oncolytics Biotech Inc. today announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA) in combination with REOLYSIN (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024).

19 Jan 2016

Researchers suggest ways to make TB drugs more efficacious against mutations

Biophysicists have discovered why the bacteria that cause tuberculosis (TB) are naturally somewhat resistant to antibiotics known as fluoroquinolones. Their findings, based on mapping the detailed three-dimensional structure of the drugs interacting with an essential enzyme in the TB germ, also reveal why some TB drugs are more potent than others and suggest how drug developers can make fluoroquinolones more efficacious against mutations that make the lung disease drug resistant.

19 Jan 2016

BENEPALI granted marketing authorization in the EU for treatment of chronic inflammatory diseases

The joint venture between Biogen and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI , an etanercept biosimilar referencing Enbrel.

19 Jan 2016

New sites opened across the South West for Alzheimer’s disease clinical trial

People with Alzheimer’s disease are helping with a ground-breaking government-funded trial but with new sites recently opened in the South West more people are being asked to take part in the study led by academics from the Universities of Bristol, Cambridge, Queen’s University Belfast and University College London, and hosted by North Bristol NHS Trust.

19 Jan 2016

Efficacy News and Research

Cardiovascular considerations crucial for CML TKI patients

Adjuvant Chemotherapy Colon Cancer Trials Should ‘Stratify By MSI, KRAS, BRAF’

UAB study shows IL-37 protein suppresses inflammatory response after spinal cord injury

Researchers use ASC secreted factors to create therapeutic factor concentrate for critical limb ischemia

Oral drug ivacaftor appears to be safe, beneficial to pre-school children with specific type of cystic fibrosis

Lilly receives FDA approval for Humulin R U-500 KwikPen

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Immunotherapy could be the future of cancer treatments

Gene therapy holds considerable potential for safe, effective treatment of people with factor VII deficiency

Mood disorder experts question effectiveness of metyrapone drug

Novel gene therapy treatment proves safe, effective for factor VII deficiency

New Georgia Tech research center launched to manufacture living cells for cell-based therapies

Physiotherapy and occupational therapy not effective in patients with Parkinson's disease

SIRIUS supports single-agent daratumumab in refractory multiple myeloma

Stem cell transplantation of neurotrophic factors shows promise in ALS

Text message reminders may help reduce people’s blood pressure

First patients treated in Phase 1b trial of pembrolizumab with REOLYSIN in advanced pancreatic adenocarcinoma

Researchers suggest ways to make TB drugs more efficacious against mutations

BENEPALI granted marketing authorization in the EU for treatment of chronic inflammatory diseases

New sites opened across the South West for Alzheimer’s disease clinical trial

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News